key: cord-0878492-x11ntaqf
authors: Azir, Michael; Inman, Brannon; Webb, James; Tannenbaum, Lloyd
title: STEMI Mimic - Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine
date: 2021-09-27
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2021.09.017
sha: cb2b72e3c14688c97994f85fd1da5baf8a533111
doc_id: 878492
cord_uid: x11ntaqf

Background In May 2021, the FDA expanded the emergency use authorization for the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2) to include adolescents 12-15 years of age. As vaccine administration continues to increase, potential adverse outcomes to include myocarditis are being reported to the Vaccine Adverse Event Reporting System (VAERS). Case Report This case report describes a 17 year old male who developed focal myocarditis mimicking an ST-Segment Elevation Myocardial Infarction (STEMI) 3 days after administration of an mRNA COVID-19 vaccine. Why should an emergency physician be aware of this? Myocarditis is a rare complication in adolescents receiving mRNA COVID-19 vaccines. Focal myocarditis may demonstrate localizing ECG changes consistent with a ST-Segment Elevation Myocardial Infarction. Overall, complications of the mRNA COVID-19 vaccines are extremely rare. The vaccine continues to be recommended by public health experts, as the benefits of vaccinations greatly outweigh the rare side effects.

Following a cluster of patients developing pneumonia and viral prodromal symptoms in Wuhan, China, a novel coronavirus, ultimately deemed SARS-CoV-2 was discovered. 1, 2 After over a year of causing unprecedented death, disease, and economic collapse, the first vaccine in America was given in New York City on Dec 14, 2020 . Initially, this vaccine was only approved for adults age 18 and older, however, effective May 2021, the emergency use authorization (EUA) was amended to allow the BNT162b2 SARS-CoV-2 vaccination to be administered to those between the ages of 12 and 18 years old. 3 As of June 27, 2021, over 323,000,000 vaccines have been administered in the United States with the majority being the mRNA subtype. Adverse outcomes of the mRNA COVID-19 vaccines are rare but do include myocarditis, anaphylaxis, and death. 4 Sparse evidence exists regarding the incidence of myocarditis following mRNA vaccination, however cases are beginning to be reported. 5, 6 With the exception of the smallpox vaccination, post vaccination myocarditis is thought to be a relatively rare occurrence. 5, 7 We present a case of focal myocarditis mimicking an ST-Segment Elevation Myocardial Infarction (STEMI) in a 17-year-old patient following BNT162b2 mRNA SARS-CoV-2 vaccination.

In June of 2021, an otherwise healthy, thin 17-year-old male, presented to the Emergency Department with 3 days of progressively worsening substernal chest pain and exertional dyspnea that began one day after his second BNT162b2 vaccination. He had no family history of premature coronary artery disease. Upon presentation, the patient's vitals were within normal limits; blood pressure 119/79, heart rate 90 bpm, respiration rate 16, pulse ox 97% on room air.

His physical exam was benign including lungs clear to auscultation, no murmurs/rubs/gallops on cardiac exam, and non-reproducible chest pain. The patient's chest x-ray showed no acute cardiopulmonary abnormalities. The initial electrocardiogram (ECG) (Figure 1 ) showed sub-1mm lateral ST elevations with sub-1mm depression in lead III. Bedside ultrasound showed a trace pericardial effusion without wall motion abnormalities. Initial troponin was elevated at 0.08ng/mL (nl <0.03ng/mL). Repeat ECG ( Figure 2 ) demonstrated 1mm elevations in leads I and aVL with reciprocal depression in lead III. At this time cardiology was consulted and a code STEMI was called given localizing ECG changes meeting STEMI criteria. The patient was given 324mg of aspirin and sublingual nitroglycerin without improvement in the patient's chest pain.

Intravenous diltizem was then administered for concerns of possible coronary vasospasm without improvement in the patient's chest pain or normalization of the patient's ECG.

Cardiology elected to obtain a Coronary Computed Tomography Angiogram (CCTA), as there was high suspicion for myocarditis and low suspicion for acute coronary syndrome given the patient's age and lack of risk factors. The CCTA showed normal coronary origins with a Coronary Artery Calcium (CAC) score of 0. Repeat troponin returned at 0.22ng/mL.The patient was then admitted to the Cardiology service for suspected myocarditis. C-Reactive Protein was noted to be elevated at 1.9mg/dL (nl <=0.5mg/dL) while the Erythrocyte Sedimentation Rate was normal at 14mm/hr (nl 0-20mm/hr). Trended troponins continued to rise with a peak value of 0.39ng/mL. A Cardiac MRI was performed and showed diffuse, sub-epicardial delayed gadolinium enhancement of the anterior and lateral wall of the left ventricle, with corresponding heterogeneous T1 signal prolongation and increased STIR signal consistent with a high risk pattern for myocarditis as depicted in Figure 3 ; left ventricular ejection fraction was preserved at 55%. The patient was monitored on the Cardiology service for 1 day and was discharged after subsequent troponins downtrended with plans for close follow up with the cardiology department. The patient followed up in the Pediatric Cardiology clinic 1 month after discharge and endorsed complete resolution of symptoms. No additional labs or imaging were completed at this time. He was placed on a 6 month activity restriction.

Although the BNT162b2 was the first mRNA vaccine approved for emergency use authorization by the FDA, the vaccine strategy is not new. In 1990, mRNA was injected into mouse skeletal muscle in vivo resulting in transcription of proteins. 8 The mRNA COVID-19 vaccine contains nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2. 9 The body's immune response to these immunogens is believed to cause a suspected hypersensitivity myocarditis although the mechanism is not yet known. Antibody mediated responses to the spike proteins have also been theorized. New research suggests that elevated levels of anti-spike IgG may be linked to more severe systemic infection. 10 Biologic agents such as fostamatinib, a therapeutic small-molecule inhibitor of Syk kinase approved by the FDA, are currently being studied to decrease said response. 10 Myocarditis is defined as inflammation of the cardiac myocardium and it is caused by immune mediated, toxic, and infectious, most commonly viral, etiologies. 11 With the exception of the smallpox vaccination, post vaccination myocarditis is thought to be a relatively rare occurrence. 5, 7 Recent reports of myocarditis following novel Emergency Use Authorized vaccines raise concern for a possible trend of adverse effects. 5 According to CDC reports and Vaccine Adverse Event Reporting System (VAERS) data, there were 573 reports of myocarditis and pericarditis after 2 doses of an mRNA with a predilection for affecting young adolescent males (data through May 31, 2021). 13 In the 16-39 age group, a rate of 16.1 per 1 million vaccine doses, or 0.00161%, is reported to VAERS. 13 It is unknown what the true rate of myocardial involvement is in SARS-CoV-2 infection but estimates range from 7-23%. 14 Most patients recover with minimal sequelae, though ventricular arrhythmias are more common in those with healed myocarditis. 1, 12, 14 Clinical presentations of myocarditis can vary widely from non-specific symptoms like chest tightness and shortness of breath to fulminant heart failure. The differential for myocarditis includes acute coronary syndrome, septic myocardial malfunction, and cardiac myopathy. 1 Laboratory diagnostic modalities typically include metabolic panel, cardiac troponin T, brain natriuretic peptide, and electrocardiogram. 1 ECG changes are often diffuse and non-specific although focal myocarditis may result in ECG changes that can mimic an acute coronary syndrome, such as this case. 15 For patient with findings concerning for myocarditis American Heart Association guidelines recommend one or more cardiac imaging modalities which may include echocardiogram or magnetic resonance imaging. 1 Cardiac catheterization is performed at the discretion of the cardiologist, however some argue there should be a consideration for endomyocardial biopsy at the time of the procedure. 1 Management of myocarditis from any cause is largely supportive. 1, 5, 14 While reported cases of myocarditis with the mRNA SARS-CoV-2 vaccine exist, the rate of myocardial involvement following vaccination appears to be significantly less than the rate of myocardial involvement from SARS-CoV-2 infection. In light of the greater public health concern surrounding SARS-CoV-2 infection, authorities still recommend vaccination as it is likely safer than infection from the representative virus. 12, 13 Why should an emergency physician be aware of this?

As vaccine administration continues to increase, possible adverse outcomes to include myocarditis are becoming more widely recognized. Focal myocarditis may demonstrate 

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

A Novel Coronavirus from Patients with Pneumonia in China

Emergency Use Authorization (EUA) Amendment for an Unapproved Product Review Memorandum Identifying Information Application Type EUA (Event-Driven EUA Request) Amendment Application Number EUA 27034 (Amendment 132) Sponsor Pfizer

html#:~:text=Anaphylaxis%20after%20COVID%2D19%20vaccination,and%20im mediately%20treat%20the%20reaction

Myocarditis following COVID-19 mRNA vaccination

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military

Smallpox vaccination and myopericarditis: A clinical review

Direct gene transfer into mouse muscle in vivo

Bnt162b vaccines protect rhesus macaques from sars-cov-2

High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages

Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

SARS-CoV-2 Vaccines: Status Report

Vaccines and Related Biological Products Advisory Committee

COVID-19 and Myocarditis: What Do We Know So Far? CJC Open

Viral myocarditis mimicking acute myocardial infarction